The Federal Trade Commission is not expected to challenge UnitedHealth Group's acquisition of home health firm LHC Group, Seeking Alpha reported Jan. 31, citing a CTFN report.
The news comes after Capitol Forum reported Jan. 26 that the FTC was reviewing the planned acquisition under a "potential vertical harm theory." CTFN said in its report that legal arguments about vertical theories of harm are unlikely to effectively halt the deal.
CTFN said in a Jan. 18 report that the deal may receive unconditional approval from the FTC.
UnitedHealth's Optum in March agreed to buy Lafayette, La.-based LHC Group in a $5.4 billion deal. In June, the FTC requested additional information regarding the proposed acquisition. In December, the companies said they had complied and expected the deal to close in the first quarter of 2023. The termination date for the agreement was also extended until March 28.